Optogenetic Therapy Shows Efficacy in Autosomal Recessive Retinitis Pigmentosa

Results from a phase 1/2 study from Nanoscope Therapeutics were presented at the 2021 ASRS meeting.

Ide-Cel's Benefit on PF Survival: Doris Hansen, MD

The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.

GeneTherapyLive’s Weekly Rewind – October 15, 2021

Review top news and interview highlights from the week ending October 15, 2021.

Identifying Patient-Specific Tumor Targets

Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.

Study Investigates New CAR T Therapy for T-Cell Lymphoma

The study follows Legend Biotech’s initial success with cilta-cel, whose PDUFA date is set for November 2021.

CAR T Therapies for Hematologic Malignancies and Solid Tumors

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed therapies the company is developing.